Document is current
Any future updates will be listed below
-
Authors
Qassem, Shahd
Naidu, Gonna Somu https://orcid.org/0000-0003-4822-0259
Goldsmith, Meir
Breier, Dor https://orcid.org/0000-0001-7397-2562
Rampado, Riccardo
Ramishetti, Srinivas
Keller, Michael
Schumacher, Felix
Lassen, Kara G.
Otikovs, Leilah https://orcid.org/0000-0001-7641-4873
Kamyshinsky, Roman
Hazan-Halevy, Inbal
Peer, Dan https://orcid.org/0000-0001-8238-0673
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 7 August 2025
First Online: 18 August 2025
Competing interests
: D.P. receives licensing fees (to patents on which he was an inventor) from, invests in, and consults (or on scientific advisory boards or boards of directors) for lecturing (and received a fee), or conducts sponsored research at TAU for the following entities: ART Biosciences, BioNtech SE, Earli Inc., Kernal Biologics, LAND Therapeutics, Merck, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, Teva Pharmaceuticals Inc. M.K., F.S., and K.G.L. are employees of Roche. All other authors declare no competing interests.
